Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study.
Andrew Whitman, Kathlene DeGregory, Amy Morris...
https://pubmed.ncbi.nlm.nih.gov/29869294/Actively Recruiting
Led by Iuliu Hatieganu University of Medicine and Pharmacy · Updated on 2026-02-13
120
Participants Needed
1
Research Sites
52 weeks
Total Duration
Cancer patients in palliative care often take many medications, which can increase the risk of drug-related problems, including adverse reactions and hospitalizations. This research studies cancer patients attitudes toward stopping non-cancer medications, a process called deprescribing, and examines how well patients understand medical information. The study also evaluates whether an educational intervention by a clinical pharmacist can improve patient engagement and knowledge about their medications. Participants will first complete two validated questionnaires in Romanian one assessing attitudes toward deprescribing rPATD, and another measuring health literacy HLS-EU-Q16. After this, they will receive educational materials including a brochure and a video explaining deprescribing, medication effectiveness, adverse reactions, and the patients role in treatment decisions. Participants will complete the rPATD questionnaire again at their next cancer treatment cycle, which occurs after 14, 21, or 28 days. Throughout the study, participants will answer questionnaires about their views on deprescribing and their understanding of health information. Researchers will measure changes in attitudes toward stopping medications before and after the educational intervention and assess health literacy at enrollment. The study lasts from enrollment until the next cancer treatment cycle, with timing depending on the participants treatment schedule.
CONDITIONS
Attitudes Towards Deprescribing Medications in Cancer Patients and Impact of Educational Intervention by a Clinical Pharmacist
M
Mihaela I Clinical pharmacist, PhD student
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Iuliu Hatieganu University of Medicine and Pharmacy
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 14 to 28 days depending on cancer treatment cycle
Participants complete questionnaires about their medication attitudes and health literacy, then receive a brochure and video about deprescribing and medication information. At their next cancer treatment cycle, they complete a follow-up questionnaire.
2 visits (questionnaire and follow-up)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Andrew Whitman, Kathlene DeGregory, Amy Morris...
https://pubmed.ncbi.nlm.nih.gov/29869294/Amy Linsky, Walid F Gellad, Jeffrey A Linder...
https://pubmed.ncbi.nlm.nih.gov/31430394/Madalina Adina Coman, Alina Ioana Forray, Stephan Van den Broucke...
https://pubmed.ncbi.nlm.nih.gov/35185446/Emily Reeve, Lee-Fay Low, Sepehr Shakib...
https://pubmed.ncbi.nlm.nih.gov/27785734/C Bucsa, M Onea, A Rusu...
https://pubmed.ncbi.nlm.nih.gov/37495451/Iuliu Hatieganu University of Medicine and Pharmacy
Lead Sponsor